Nuzenio

Tradingview Celldex Therapeutics

Tradingview Celldex Therapeutics entity intelligence is not indexable yet because Nuzenio needs more live source-attributed coverage.

topic 6 latest news signals 1 publisher sources 100/100 entity strength

Latest news

Fri, 07 Aug 2026 13:20:11 GMTCelldex Therapeutics, Inc. Stock 12‑Month Price Target Raised to $58.07, Implies 40% Upside - TradingView

Thu, 06 Aug 2026 20:34:31 GMTCelldex Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary - TradingView

Thu, 06 Aug 2026 20:11:01 GMTCelldex Therapeutics, Inc. 2026: Revenue $22K, EPS ($0.94) — 10-Q Summary - TradingView

Thu, 06 Aug 2026 20:04:13 GMTCLDX: Barzolvolimab Phase 3 trials progress rapidly; cash reserves support operations through 2028 - TradingView

Thu, 06 Aug 2026 20:03:01 GMTCelldex reports Q2 net loss of $73.5M; cash and marketable securities $717.6M at June 30, 2026 - TradingView

Wed, 05 Aug 2026 11:00:57 GMTCLDX Q2'26 Earnings: EPS estimate is (1.06) USD - TradingView

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Tradingview Celldex Therapeutics.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

1 distinct publisher/source names are currently connected to this entity page.